This undated photo provided by Eisai Co., Ltd., shows Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies. Japan's health ministry has approved Leqembi, the first drug for the treatment of the disease in a country with a rapidly aging population. Leqembi was developed by Japanese drugmaker Eisai and U.S. biotechnology firm Biogen. (Eisai Co., Ltd. via AP)